Dermato-oncology

Non-melanoma skin cancer (NMSC) is responsible for a higher worldwide mortality rate compared to melanoma, a more severe type of skin cancer. A comprehensive analysis of global skin cancer incidence and mortality assessed global skin cancer epidemiology, emphasizing incidence, mortality, risk profiles, and dermatologist density’s impact. touchDERMATOLOGY caught up with Prof. Thierry Passeron (University Hospital of Nice, Nice, France) to discuss the key outcomes and the likely impact the findings will have on clinical practice. The abstract 'A comprehensive analysis of global skin cancer incidence and mortality with a focus on dermatologist density and population risk factors' (Abstract N°: P1519) was presented at EADV 2023, Berlin, 11-14 October 2023 #EADVCongress. Questions What is the global burden of non-melanoma skin cancer? (0:11) What were the key outcomes from your study of WHO International Agency for Research on Cancer? (0:38) What impact will these findings have on clinical practice? (1:58) Disclosures: Thierry Passeron has been a consultant for Almirall, Abbvie, Amgen, Astellas, BMS, Celgene, Galderma, GSK, Incyte, Isocell, Janssen, LEO Pharma, Lilly, MSD, Novartis, Pfizer, Sanofi-Genzyme, SUN pharma, UCB pharma; received grant/research support from Abbvie, Almirall, BMS, Celgene, Incyte, Isocell, LEO Pharma, Lilly; and has received honorarium from Almirall, Abbvie, Amgen, Astellas, BMS, Celgene, Galderma, GSK, Incyte, Isocell, Janssen, LEO Pharma, Lilly, MSD, Novartis, Pfizer, Sanofi-Genzyme, SUN pharma, UCB pharma. Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones and Katey Gabrysch. Filmed in coverage of the EADV Annual Meeting. This content was developed by Touch Medical Media and is not affiliated with the  European Academy of Dermatology & Venereology  (EADV) or the congress. 

Brentuximab vedotin, an antibody–drug conjugate, was approved for the treatment of cutaneous T-cell lymphoma (CTCL) in Europe in 2017. In this touchDERMATOLOGY interview, we spoke with Prof. Adam Reich (University of Medicine, Wroclaw, Poland) to discuss the rationale and findings from his observational open-label study of brentuximab vedotin for CTCLs, assessing the real-world efficacy and safety of the ADC in Poland. The abstract ‘Real-world outcomes of brentuximab vedotin treatment in patients with CD30-expressing cutaneous T-cell lymphoma: 24‑week interim analysis of a prospective, multicenter, observational study in Poland.’ (Abstract N°: 6587) was presented at EADV 2023, Berlin, 11-14 October 2023 #EADVCongress. Questions What challenges are associated with treating advanced cutaneous T-cell lymphomas (CTCLs)? (0:21) Could you give us a brief overview of the findings from the phase 3 ALCANZA trial? (0:54) What were the aims and design of the observational open-label study you presented at EADV? (1:55) What were the real-world efficacy and safety findings from your study? (2:37) How will these insights optimise the use of brentuximab vedotin for CTCLs? (3:19) Disclosures: Adam Reich discloses receiving grant/research support from Abbvie, Anaptys, BMS, Dice, Eli Lilly, Galderma, Incyte, Jannsen, Medac, Novartis, Pfizer, Regeneron, Trevi Therapeutics, and UCB; serving on advisory boards for Abbvie, Galderma, Leo Pharma, Sanofi, Novartis, and Eli Lilly. Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones and Katey Gabrysch. Filmed in coverage of the EADV Annual Meeting. This content was developed by Touch Medical Media and is not affiliated with the  European Academy of Dermatology & Venereology  (EADV) or the congress.